search
Back to results

The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury

Primary Purpose

Neuropathic Pain, Depression, Cognitive Impairment

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Omega-3
Vegetation Protein Powder
InflanNox
Anti-oxidant Network
Chlorella
Sponsored by
Brock University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neuropathic Pain focused on measuring Chronic Inflammation, Spinal Cord Injury, Anti-inflammatory Diet, Neuropathic Pain, Depression, Cognitive Impairment, Somatic Nerve Function, Autonomic Nerve Function

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Individuals with Spinal Cord Injury over the age of 18

Exclusion Criteria:

  • Any allergies / food intolerances to any supplements used in the study. Any participants who are pregnant, breast feeding, diabetic, or have kidney disease will also be excluded.

Sites / Locations

  • Brock University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Anti-inflammatory Supplementation

Arm Description

Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily

Outcomes

Primary Outcome Measures

Change from baseline in nerve conduction velocity of somatic nerves at 3 and 6 months
Assessment of motor and sensory nerve conduction velocity via electrically evoked potentials of the median nerve

Secondary Outcome Measures

Change in baseline in autonomic function scores on the Autonomic Standards Assessment Form at 3 and 6 months
Questionnaire pertaining to urinary, bowel, and sexual function
Change in baseline pain scores on the Neuropathic Pain Questionnaire at 3 and 6 months
Questionnaire pertaining to the type of pain felt (eg. burning, stabbing, throbbing), how the pain affects the participant (eg. ability to perform activities of daily living), and how various stimuli may increase pain (eg. increased pain due to heat).
Change in baseline concentrations of pro-inflammatory eicosanoids at 3 and 6 months
The potent pro-inflammatory and pain inducing eicosanoids prostaglandin-2 (PGE2) and leukotriene-4 (LTB4) as well as the less potent eicosanoids prostaglandin-3 and leukotriene-5 (LTB5) will be assessed.
Change in baseline depression scores on the Centre for Epidemiological Studies Depression Scale at 3 and 6 months
Questionnaire pertaining to how often participants felt a variety of depressive symptoms over the previous 7 days.
Change in baseline concentrations of peripheral tryptophan and other large neutral amino acids at 3 and 6 months
The amino acid tryptophan (TRP) as well as other large neutral amino acids (LNAA) including leucine, isoleucine, valine, and tyrosine will be assessed to determine the TRP/LNAA ratio.
Change in baseline episodic learning and memory scores on the California Verbal Learning Test at 3 and 6 months
Verbal test of word recall.
Change in baseline concentrations of serum tryptophan and kynurenine levels at 3 and 6 months

Full Information

First Posted
March 24, 2014
Last Updated
July 28, 2015
Sponsor
Brock University
Collaborators
Ontario Neurotrauma Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02099890
Brief Title
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
Official Title
Neural Consequences of Chronic Inflammation in Individuals With Spinal Cord Injury and the Influence of an Anti-inflammatory Diet
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
September 2014 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brock University
Collaborators
Ontario Neurotrauma Foundation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Spinal cord Injury (SCI) is a condition commonly associated with a state of chronic low-grade inflammation due to a variety of factors such heightened risk for infection and development of metabolic disorders. Many disorders which have been demonstrated to have an inflammatory basis have also been found to be at much higher prevalence following SCI. Such conditions include, but are not limited to, depression, cognitive impairment, neuropathic pain, and somatic/autonomic nerve function. The fact that such disorders have an inflammatory basis provides a unique opportunity to treat them with intervention strategies which target the immune system. Natural anti-inflammatory interventions including a diet consisting of foods and supplements with anti-inflammatory properties may be an effective option for treating inflammation in this population. As this treatment strategy will target the inflammatory basis of many disorders it would be expected to lead to a reduction in pro-inflammatory mediators thereby leading to more sustainable long-term immune improvements regarding enzyme function and protein balances. Despite this, surprisingly little research has focused on the use of anti-inflammatory foods for the treatment of chronic inflammatory conditions, and effects specific to SCI have been almost completely neglected. As such, the current study will focus on the daily intake of natural supplements with anti-inflammatory properties over a 3 month intervention and the effects on inflammation and associated disorders will be assessed. It is hypothesized that the supplementation will result in positive alterations in enzyme regulation and protein balances resulting in improvements in each of the outcome measures of interest.
Detailed Description
Spinal cord injury (SCI) is a condition commonly associated with a state of chronic inflammation due to a number of factors. A loss of motor and sensory function typically results in a greater susceptibility to the development of acute secondary health complications such as urinary tract infections and pressure sores resulting in frequent bouts of inflammation. The loss of mobility also places these individuals at an elevated risk for the development of a variety of metabolic disorders such as obesity and type 2 diabetes; each of which are independently associated with chronic inflammation. Additionally, elevated levels of circulating proinflammatory cytokines and autoantibodies have been shown to be present in the serum of individuals with SCI even when asymptomatic for other secondary health complications. As such, following SCI, individuals are commonly in a state of perpetual low grade inflammation. It has yet to be established whether or not such elevations in proinflammatory mediators are beneficial to patients or if they are in fact surrogate markers of further neurological impairment. Such mediators play critical roles tissue repair however, it is also well established that the immune system has the ability to communicate with other systems of the body. As such, the immune system has the ability to influence and be influenced by other systems suggesting that immune dysfunction has the capability (and likelihood) of influencing the nervous system to some degree. A variety of neurological and behavioural disorders including depression, cognitive impairment, and neuropathic pain have each been linked to a state of chronic inflammation and are each at a dramatically elevated prevalence following SCI. Pro-inflammatory mediators have been suggested to influence the nervous system via both direct and indirect mechanisms. There is evidence to suggest cytokines may directly influence somatic nerves by altering ion channel kinetics through channelopathy. Pro-inflammatory cytokines have also been shown to possess the ability to up-regulate key enzymes resulting in protein imbalances and/or increased production of neuromodulatory proteins, which may influence the severity of a variety of neural disorders. Presently, the majority of treatment strategies for conditions such as major depression and pain utilize drug treatments which target "downstream" enzymes and receptors. As such, these treatments provide fairly rapid and affective relief from symptoms. However, as this strategy does not target the inflammatory basis of such disorders it provides only a temporary solution whereby symptoms are likely to return upon the cessation of the treatment. In addition, long term use of certain drug treatments such as selective serotonin re-uptake inhibitors (SSRI's) may only enhance biochemical vulnerability and exacerbate symptoms long-term. An understanding of how the immune and nervous systems interact may provide a unique opportunity to treat neural and behavioral disorders by targeting aspects of the immune system via anti-inflammatory interventions. Natural anti-inflammatory interventions including a diet consisting of foods and supplements with anti-inflammatory properties may be an effective option for treating inflammation in this population. As this treatment strategy will target the inflammatory basis of many disorders it would be expected to lead to a reduction in pro-inflammatory mediators thereby leading to more sustainable long-term immune improvements. Despite this, surprisingly little research has focused on the use of anti-inflammatory foods for the treatment of chronic inflammatory conditions, and effects specific to SCI have been almost completely neglected. The research objective of the present study is to evaluate the effects of a reduced inflammatory state by means of an anti-inflammatory diet on depression, cognitive impairment, neuropathic pain, and somatic and autonomic nerve function. Participants will be placed on a 3 month anti-inflammatory diet consisting of daily supplementation including omega-3 polyunsaturated fatty acids, InflanNox (curcumin), anti-oxidants, chlorella, and a vegetarian protein powder. A focus on foods and supplements with natural anti-inflammatory properties is expected to lead to beneficial reductions in the incidence of infections as well as positive metabolic adaptations. Together, this should help to reduce elevated levels of proinflammatory mediators. It is hypothesized that a reduction in pro-inflammatory mediators will result in positive alterations in enzyme regulation leading to beneficial changes in protein balances and ultimately improvements in each of the measures of outcome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neuropathic Pain, Depression, Cognitive Impairment, Somatic Neuropathy, Autonomic Dysfunction
Keywords
Chronic Inflammation, Spinal Cord Injury, Anti-inflammatory Diet, Neuropathic Pain, Depression, Cognitive Impairment, Somatic Nerve Function, Autonomic Nerve Function

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Anti-inflammatory Supplementation
Arm Type
Experimental
Arm Description
Omega-3 pill (500 EPA / 250 DHA) taken orally 3 times daily, Vegetation Protein Powder (45g) taken orally once daily, InflanNox capsule (400mg curcumin) taken 3 times daily, Anti-oxidant Network capsule (615mg) taken twice daily, Chlorella tablet (1000mg) taken 6 times daily
Intervention Type
Dietary Supplement
Intervention Name(s)
Omega-3
Other Intervention Name(s)
Now Ultra Omega-3
Intervention Type
Dietary Supplement
Intervention Name(s)
Vegetation Protein Powder
Other Intervention Name(s)
Progressive Veggessential Protein Powder
Intervention Type
Dietary Supplement
Intervention Name(s)
InflanNox
Other Intervention Name(s)
AOR InflanNox, Curcumin
Intervention Type
Dietary Supplement
Intervention Name(s)
Anti-oxidant Network
Other Intervention Name(s)
CanPrev Anti-oxidant Network
Intervention Type
Dietary Supplement
Intervention Name(s)
Chlorella
Other Intervention Name(s)
Now Chlorella
Primary Outcome Measure Information:
Title
Change from baseline in nerve conduction velocity of somatic nerves at 3 and 6 months
Description
Assessment of motor and sensory nerve conduction velocity via electrically evoked potentials of the median nerve
Time Frame
Baseline / 3 months / 6 months
Secondary Outcome Measure Information:
Title
Change in baseline in autonomic function scores on the Autonomic Standards Assessment Form at 3 and 6 months
Description
Questionnaire pertaining to urinary, bowel, and sexual function
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline pain scores on the Neuropathic Pain Questionnaire at 3 and 6 months
Description
Questionnaire pertaining to the type of pain felt (eg. burning, stabbing, throbbing), how the pain affects the participant (eg. ability to perform activities of daily living), and how various stimuli may increase pain (eg. increased pain due to heat).
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline concentrations of pro-inflammatory eicosanoids at 3 and 6 months
Description
The potent pro-inflammatory and pain inducing eicosanoids prostaglandin-2 (PGE2) and leukotriene-4 (LTB4) as well as the less potent eicosanoids prostaglandin-3 and leukotriene-5 (LTB5) will be assessed.
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline depression scores on the Centre for Epidemiological Studies Depression Scale at 3 and 6 months
Description
Questionnaire pertaining to how often participants felt a variety of depressive symptoms over the previous 7 days.
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline concentrations of peripheral tryptophan and other large neutral amino acids at 3 and 6 months
Description
The amino acid tryptophan (TRP) as well as other large neutral amino acids (LNAA) including leucine, isoleucine, valine, and tyrosine will be assessed to determine the TRP/LNAA ratio.
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline episodic learning and memory scores on the California Verbal Learning Test at 3 and 6 months
Description
Verbal test of word recall.
Time Frame
Baseline / 3 months / 6 months
Title
Change in baseline concentrations of serum tryptophan and kynurenine levels at 3 and 6 months
Time Frame
Baseline / 3 months / 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Individuals with Spinal Cord Injury over the age of 18 Exclusion Criteria: Any allergies / food intolerances to any supplements used in the study. Any participants who are pregnant, breast feeding, diabetic, or have kidney disease will also be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David S. Ditor, PhD.
Organizational Affiliation
Brock University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David J. Allison, MSc.
Organizational Affiliation
Brock University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Brock University
City
St Catharines
State/Province
Ontario
ZIP/Postal Code
L2S 3A1
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
26545369
Citation
Allison DJ, Ditor DS. Targeting inflammation to influence mood following spinal cord injury: a randomized clinical trial. J Neuroinflammation. 2015 Nov 6;12:204. doi: 10.1186/s12974-015-0425-2.
Results Reference
derived

Learn more about this trial

The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury

We'll reach out to this number within 24 hrs